Author

B. Haley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

A. Heidersbach· 2 shared A. J. Heidersbach· 2 shared A.-J. Tong· 2 shared C. Blanchette· 2 shared C. M. Rose· 2 shared M. Beresini· 2 shared Y. Abdolazimi· 2 shared A. Ashkenazi· 1 shared

Activity by Year

2018-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Heidersbach

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

HLApollo: A superior transformer model for pan-allelic peptide-MHC-I presentation prediction, with diverse negative coverage, deconvolution and protein language features.

W. J. Thrift, N. W. Lounsbury, Q. Broadwell, A. Heidersbach, E. Freund, Q. Phung, Y. Abdolazimi, J. Chen, A.-H. Capietto, A.-J. Tong, C. M. Rose, C. Blanchette, J. Lill, B. Haley, L. Delamarre, , S. Jhunjhunwala

HLApollo improves MHC-I peptide presentation prediction with a transformer model, showing better performance than existing methods and offering pan-allelic generalization.

bioRxiv · Dec 8, 2022 · PreprintImmunology

Discovery of prevalent, clinically actionable tumor neoepitopes via integrated biochemical and cell-based platforms

H. Gurung, A. J. Heidersbach, M. Darwish, P. Chan, J. Li, M. Beresini, O. Zill, A. Wallace, A.-J. Tong, D. Hascall, E. Torres, A. Chang, K. Lou, Y. Abdolazimi, U. Uche, , C. M. Rose

The paper identifies 84 clinically relevant neoepitope-HLA pairs from 37 shared cancer neoantigens using a combination of biochemical assays and computational methods.

bioRxiv · Oct 27, 2022 · PreprintCancer Biology

A versatile, high-efficiency platform for CRISPR-based gene activation

A. J. Heidersbach, K. M. Dorighi, J. A. Gomez, A. M. Jacobi, B. Haley

This paper introduces a high-efficiency CRISPRa platform combining piggyBac transposon technology and optimized guide RNA scaffolds to enable rapid, stable gene activation in diverse cellular contexts.

bioRxiv · Jul 21, 2022Bioengineering

G9a methyltransferase governs cell identity in the lung and is required for KRAS G12D tumor development and propagation

A. Pribluda, A. Daemen, A. N. Lima, X. Wang, M. Hafner, C. Poon, Z. Modrusan, A. K. Katakam, O. Foreman, J. Eastham, J. Hung, B. Haley, J. T. Garcia, E. L. Jackson, M. R. Junttila

This study shows G9a methyltransferase regulates Wnt signaling in lung development and tumor progression by controlling β-catenin transcriptional activity, and its inhibition prevents KrasG12D lung cancer.

bioRxiv · Apr 20, 2020 · PreprintCancer Biology

Disruption of IRE1α through its Kinase Domain Attenuates Multiple Myeloma

J. M. Harnoss, A. Le Thomas, S. A. Marsters, D. A. Lawrence, M. Lu, Y.-C. A. Chen, J. Qing, K. Totpal, D. Kan, E. Segal, H. Ackerly Wallweber, W. Wang, K. Clark, S. Kaufman, M. Beresini, , A. Ashkenazi

This study shows that disrupting IRE1α's kinase domain reduces multiple myeloma tumor growth and enhances treatment efficacy, suggesting it as a therapeutic target.

bioRxiv · Dec 14, 2018 · PreprintCancer Biology